Literature DB >> 1394781

Evaluating the efficacy of chloroquine in febrile Guinean children infected with Plasmodium falciparum by a simplified in vivo test.

C Turaman1, L K Basco, J Le Bras.   

Abstract

A modified version of a simplified in vivo test was applied to assess the susceptibility of Plasmodium falciparum to chloroquine among semi-immune febrile children in Kouroussa, Guinea. In 27% of cases, a partial response (RI/RII) to chloroquine was observed; the remainder showed a good response (S/RI). This test is both practical and useful to assess the efficacy of chloroquine at the intermediate level of health care services.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394781      PMCID: PMC2393378     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

1.  Monitoring the response of malaria infections to treatment.

Authors:  K H Rieckmann
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

2.  Combating severe malaria in African children.

Authors:  J G Breman; C C Campbell
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

3.  Monitoring selective components of primary health care: methodology and community assessment of vaccination, diarrhoea, and malaria practices in Conakry, Guinea. ACSI-CCCD team.

Authors:  F Dabis; J G Breman; A J Roisin; F Haba
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

  3 in total
  2 in total

Review 1.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.

Authors:  N J White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 2.  Malaria epidemiology and anti-malarial drug efficacy in Guinea: a review of clinical and molecular studies.

Authors:  Mahamoud Sama Cherif; Prabin Dahal; Abdoul Habib Beavogui; Alexandre Delamou; Eugene Kaman Lama; Alioune Camara; Mamadou Pathe Diallo
Journal:  Malar J       Date:  2021-06-16       Impact factor: 2.979

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.